Cutaneous T-cell lymphoma with HTLV-I infection: clinical overlap with adult T-cell leukemia/lymphoma

Int J Dermatol. 2006 Apr;45(4):447-9. doi: 10.1111/j.1365-4632.2006.02687.x.

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is a malignant proliferation of mature helper T lymphocytes,(1) and is caused by human T-lymphotropic virus type I (HTLV-I);(2) an HTLV-I infection endemic in the Caribbean, south-western Japan, South America and Africa.(3,4) Seroepidemiological studies suggest that it is also endemic in Brazil.(5) Although carriers of HTLV-I show polyclonal integration of virus in T lymphocytes, only patients with ATLL of various subtypes show monoclonal integration of HTLV-I in tumor cells.(6,7) Cutaneous T-cell lymphomas (CTCL) are a group of primary cutaneous lymphoproliferative diseases(8) with unknown etiology.(9) The two most common presentations of CTCL are mycosis fungoides (MF) and Sézary syndrome (SS).(10-13) However, both CTCL categories can easily resemble ATLL. Therefore, in HTLV-I endemic areas, differentiation between ATLL and CTCL must be performed, as they have different prognoses and treatment approaches.(14).

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brazil
  • Cyclophosphamide / therapeutic use
  • DNA, Viral / analysis
  • Doxorubicin / therapeutic use
  • Endemic Diseases
  • Humans
  • Interferon-alpha / therapeutic use
  • Leukemia-Lymphoma, Adult T-Cell / diagnosis*
  • Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • Male
  • Neoplasm Recurrence, Local
  • Polymerase Chain Reaction
  • Prednisone / therapeutic use
  • Vincristine / therapeutic use
  • Zidovudine / therapeutic use

Substances

  • Antineoplastic Agents
  • DNA, Viral
  • Interferon-alpha
  • Zidovudine
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol